Breaking News

Clementia Pharmaceuticals Raises $60 Million

Funds will support development of palovarotene for fibrodysplasia ossificans progressiva

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Clementia Pharmaceuticals has completed a $60 million mezzanine round of financing to support the ongoing development of the company’s lead compound palovarotene for the treatment of fibrodysplasia ossificans progressiva (FOP). New Enterprise Associates (NEA) was the lead investor with participation by UCB, RA Capital Management, Rock Springs Capital Management, EcoR1 Capital, and a fund advised by Janus Capital Management LLC as well as existing investors OrbiMed Advisors and BDC Capital ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters